Effect of probiotics and incretine mimeticss on the levels of glucagon-like peptide-1 in blood serum of patients with type 2 diabetes mellitus

Authors

  • K.A. Shyshkan-Shyshova State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Science of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0003-0939-5902
  • O.V. Zinych State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Science of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0002-0516-0148
  • N.M. Kushnareva State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Science of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0002-5390-6784
  • A.V. Кovalchuk State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Science of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0001-6591-1460
  • O.V. Prybyla State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Science of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0003-2212-1172

DOI:

https://doi.org/10.22141/2224-0721.17.8.2021.246792

Keywords:

type 2 diabetes mellitus, glucagon-like peptide-1, intestinal microbiota, probiotics, incretine mimetics, body composition

Abstract

Background. Type 2 diabetes mellitus is characterized by a violation of the incretin effect, in particular a decrease in the secretion of glucagon-like peptide-1 (GLP-1) by intestinal endothelial cells. In recent decades, the intestinal microbiota has been shown to play a key role in the regulation of various metabolic pathways, immune system activity, and intestinal permeability. It has been shown that the composition of bacterial genera in the intestine can unfluence the effectiveness of antidiabetic drugs (eg metformin and GLP-1 receptor agonists), which may be reduced in dysbiosis. Therefore, it is of interest to study the mechanisms that mediate the effect of microbiota on the incretin secretion. The purpose was to establish the relationship between the effects of probiotic therapy, incretin therapy and the level of endogenous GLP-1 in the serum of patients with type 2 diabetes mellitus, taking into account anthropometry and body composition. Materials and methods. We examined 23 patients with type 2 diabetes mellitus (11 women and 12 men), their average age was 56.4 ± 10.5 years (M ± SD). At the beginning of the study, the mean HbA1c level was 7.7 ± 1.5 %; all patients took metformin at an average dose of 1,500 mg/day. The concentration of GLP-1 in the blood serum was determined by the enzyme-linked immunosorbent assay, anthropometry parameters and body composition were assessed using the Tanita analyzer. Results. In the group of patients who took the probiotic, a significant increase in GLP-1 was observed, but less pronounced compared to an increase in GLP-1 level in the group of patients who took GLP-1 receptor agonists. In group 2, on the background of taking GLP-1 receptor agonists, a significant decrease in body weight, total and abdominal fat content, and a decrease in dehydration were revealed. Conclusions. An increase in the concentration of endogenous GLP-1 against the background of probiotic therapy indicates a possible positive effect of normalization of the intestinal microbiota on the secretion of endogenous incretins. The results obtained suggest that the use of a combination of probiotic and GLP-1 receptor agonists may have an additive effect on the hormonal and metabolic profile in patients with type 2 diabetes mellitus.

Downloads

Download data is not yet available.

References

Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary. Endocr Pract. 2020 Jan;26(1):107-139. doi: 10.4158/CS-2019-0472.

Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006 Dec 7;355(23):2427-43. doi: 10.1056/NEJMoa066224.

Riedel AA, Heien H, Wogen J, Plauschinat CA. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen. Am J Manag Care. 2007 Aug;13(8):457-63.

Zhang Q, Hu N. Effects of Metformin on the Gut Microbiota in Obesity and Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2020 Dec 16;13:5003-5014. doi: 10.2147/DMSO.S286430.

Aydin Ö, Nieuwdorp M, Gerdes V. The Gut Microbiome as a Target for the Treatment of Type 2 Diabetes. Curr Diab Rep. 2018 Jun 21;18(8):55. doi: 10.1007/s11892-018-1020-6.

Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021 Jan;19(1):55-71. doi: 10.1038/s41579-020-0433-9.

Harsch IA, Konturek PC. The Role of Gut Microbiota in Obesity and Type 2 and Type 1 Diabetes Mellitus: New Insights into "Old" Diseases. Med Sci (Basel). 2018 Apr 17;6(2):32. doi: 10.3390/medsci6020032.

Proal AD, Lindseth IA, Marshall TG. Microbe-microbe and host-microbe interactions drive microbiome dysbiosis and inflammatory processes. Discov Med. 2017 Jan;23(124):51-60.

Rattarasarn C. Dysregulated lipid storage and its relationship with insulin resistance and cardiovascular risk factors in non-obese Asian patients with type 2 diabetes. Adipocyte. 2018;7(2):71-80. doi: 10.1080/21623945.2018.1429784.

Tanase DM, Gosav EM, Neculae E, et al. Role of Gut Microbiota on Onset and Progression of Microvascular Complications of Type 2 Diabetes (T2DM). Nutrients. 2020 Dec 2;12(12):3719. doi: 10.3390/nu12123719.

Shen J, Obin M, Zhao L. The gut microbiota, obesity and insulin resistance. Mol. Aspects Med. 2013 Feb;34(1):39-58. doi: 10.1016/j.mam.2012.11.001.

Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017 May 16;474(11):1823-1836. doi: 10.1042/BCJ20160510.

Herrema H, Niess JH. Intestinal microbial metabolites in human metabolism and type 2 diabetes. Diabetologia 2020;63(12):2533-2547. doi: 10.1007/s00125-020-05268-4.

Wang Y, Dilidaxi D, Wu Y, Sailike J, Sun X, Nabi XH. Composite probiotics alleviate type 2 diabetes by regulating intestinal microbiota and inducing GLP-1 secretion in db/db mice. Biomed Pharmacother. 2020 May;125:109914. doi: 10.1016/j.biopha.2020.109914.

Yamane S, Inagaki N. Regulation of glucagon-like peptide-1 sensitivity by gut microbiota dysbiosis. J Diabetes Investig. 2018 Mar; 9(2):262-264. doi: 10.1111/jdi.12762.

Greenhill C. Effects of metformin mediated by gut microbiota. Nat Rev Endocrinol. 2019 Dec;15(1):2. doi: 10.1038/s41574-018-0133-y.

Iulia-Suceveanu A, Micu S, Voinea C, et al. Metformin and Its Benefits in Improving Gut Microbiota Disturbances in Diabetes Patients. IntechOpen. 2019 Oct. doi: 10.5772/intechopen.88749.

Hung WC, Hung WW. 1159-P: Metformin Monotherapy Changes Gut Microbiota in Newly Diagnosed Type 2 Diabetes. Diabetes. 2019 Jun; 68(Supplement 1): -. doi: 10.2337/db19-1159-P.

Ouyang J, Isnard S, Lin J, et al. Metformin effect on gut microbiota: insights for HIV-related inflammation. AIDS Res Ther 2020 Mar 10;17(1):10. doi: 10.1186/s12981-020-00267-2.

Pascale A, Marchesi N, Govoni S, Coppola A, Gazzaruso C. The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: new insights in toold diseases. Curr Opin Pharmacol. 2019 Dec;49:1-5. doi: 10.1016/j.coph.2019.03.011.

American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S98-S110. doi: 10.2337/dc20-S009. Erratum in: Diabetes Care. 2020 Aug;43(8):1979.

Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018 Feb;20 Suppl 1:5-21. doi: 10.1111/dom.13129.

Sokolova LK, Belchina YuB, Pushkarev VV, et al. The effect of metformin treatment on the level of GLP-1, NT-proBNP and endothelin-1 in patients with type 2 diabetes mellitus. International Journal of Endocrinology (Ukraine). 2020;16(8):616-621. doi: 10.22141/2224-0721.16.8.2020.222882.

Zhao L, Chen Y, Xia F, et al. A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota. Front Endocrinol (Lausanne). 2018 May 17;9:233. doi: 10.3389/fendo.2018.00233.

Adeshirlarijaney A, Gewirtz AT. Considering gut microbiota in treatment of type 2 diabetes mellitus. Gut Microbes. 2020 May 3;11(3):253-264. doi: 10.1080/19490976.2020.1717719.

Madsen MSA, Holm JB, Pallejà A, et al. Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice. Sci Rep. 2019 Oct 30;9(1):15582. doi: 10.1038/s41598-019-52103-x.

Montandon SA, Jornayvaz FR. Effects of Antidiabetic Drugs on Gut Microbiota Composition. Genes (Basel). 2017 Sep 30;8(10):250. doi: 10.3390/genes8100250.

Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition. 2012 May;28(5):539-43. doi: 10.1016/j.nut.2011.08.013.

Shi X, Zhou F, Li X, et al. Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons. Cell Metab. 2013 Jul 2;18(1):86-98. doi: 10.1016/j.cmet.2013.06.014.

Gerritsen J, Smidt H, Rijkers GT, de Vos WM. Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr. 2011 Aug;6(3):209-40. doi: 10.1007/s12263-011-0229-7.

Roberfroid M, Gibson GR, Hoyles L, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010 Aug;104 Suppl 2:S1-63. doi: 10.1017/S0007114510003363.

He M, Shi B. Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. Cell Biosci. 2017 Oct 25;7:54. doi: 10.1186/s13578-017-0183-1.

Takemura N, Okubo T, Sonoyama K. Lactobacillus plantarum strain No. 14 reduces adipocyte size in mice fed high-fat diet. Exp Biol Med (Maywood). 2010 Jul;235(7):849-56. doi: 10.1258/ebm.2010.009377.

Delzenne NM, Neyrinck AM, Cani PD. Gut microbiota and metabolic disorders: How prebiotic can work? Br J Nutr. 2013 Jan;109 Suppl 2:S81-5. doi: 10.1017/S0007114512004047.

Parnell JA, Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr. 2009 Jun;89(6):1751-9. doi: 10.3945/ajcn.2009.27465.

Genta S, Cabrera W, Habib N, et al. Yacon syrup: beneficial effects on obesity and insulin resistance in humans. Clin Nutr. 2009 Apr;28(2):182-7. doi: 10.1016/j.clnu.2009.01.013.

Cani PD, Lecourt E, Dewulf EM, et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr. 2009 Nov;90(5):1236-43. doi: 10.3945/ajcn.2009.28095.

Honda K, Saneyasu T, Hasegawa S, Tominaga Y, Yokota S, Kamisoyama H. Effect of licorice flavonoid oil on cholesterol metabolism in high fat diet rats. Biosci Biotechnol Biochem. 2013;77(6):1326-8. doi: 10.1271/bbb.130104.

Everard A, Cani PD. Gut microbiota and GLP-1. Rev Endocr Metab Disord. 2014 Sep;15(3):189-96. doi: 10.1007/s11154-014-9288-6.

Mahboobi S, Rahimi F, Jafarnejad S. Effects of Prebiotic and Synbiotic Supplementation on Glycaemia and Lipid Profile in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Adv Pharm Bull. 2018 Nov;8(4):565-574. doi: 10.15171/apb.2018.065.

Chung HY, Cesari M, Anton S, et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev. 2009 Jan;8(1):18-30. doi: 10.1016/j.arr.2008.07.002.

Schiffrin EJ, Thomas DR, Kumar VB, et al. Systemic inflammatory markers in older persons: the effect of oral nutritional supplementation with prebiotics. J Nutr Health Aging. 2007 Nov-Dec;11(6):475-9.

Lee AY, Chappell DL, Bak MJ, et al. Multiplexed Quantification of Proglucagon-Derived Peptides by Immunoaffinity Enrichment and Tandem Mass Spectrometry after a Meal Tolerance Test. Clin Chem. 2016 Jan;62(1):227-35. doi: 10.1373/clinchem.2015.244251.

Mazur ОО, Plaksyvyi ОH, Pashkovska NV, Bilooka ІО. State of the large intestine microbiota in patients with type 1 diabetes mellitus depending on the severity of clinical course. Надійшла 2016;(77):61-66. doi: 10.22141/2224-0721.5.77.2016.78756. (in Ukrainian).

Knudsen LB. Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity. ACS Pharmacol Transl Sci. 2019 Aug 20;2(6):468-484. doi: 10.1021/acsptsci.9b00048.

Published

2022-02-23

How to Cite

Shyshkan-Shyshova, K., Zinych, O., Kushnareva, N., Кovalchuk A., & Prybyla, O. (2022). Effect of probiotics and incretine mimeticss on the levels of glucagon-like peptide-1 in blood serum of patients with type 2 diabetes mellitus. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), 17(8), 604–612. https://doi.org/10.22141/2224-0721.17.8.2021.246792

Issue

Section

Original Researches